|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
RYM - Successful completion of full bank debt refinance
Curious about dividend investment strategies?
Kiwi Property delivering on FY26 strategic priorities
Genesis Approves Investment for Edgecumbe Solar Farm
November 24th Morning Report
General Capital Announces Further Strong Growth
Comvita announces key leadership appointments
OCA - Momentum Building on Stronger Foundations
Devon Funds Morning Note - 20 November 2025
ERD - Strong cash flow supports focused ANZ market expansion